Lynk Pharma's Eczema Pill Shows Major Promise in Phase III Trial

SHANGHAI, HANGZHOU, China and BOSTON – March 02, 2026 – By Matthew Richardson

Lynk Pharmaceuticals has announced highly positive topline results from a pivotal Phase III study of its oral drug, zemprocitinib, for moderate-to-severe atopic dermatitis, signaling a potential new weapon in the fight against the debilitating skin condition. The clinical-stage company reported that its novel treatment met all primary and key secondary goals, demonstrating significant improvements in skin clearance and itch reduction compared to a placebo, coupled with a favorable safety profile.

The successful trial marks a significant milestone for Lynk, a biotech firm founded by veterans from pharmaceutical giants like Pfizer and Merck. It positions zemprocitinib as a promising new oral option for millions of patients globally who suffer from the chronic, inflammatory disease often called eczema. The results could set the stage for regulatory submissions in China and beyond, potentially disrupting a competitive market currently dominated by injectable biologics and a handful of other oral medications.

A New Contender in a Crowded Field

The treatment landscape for moderate-to-severe atopic dermatitis has evolved dramatically over the past decade. For years, patients relied on topical steroids and broad immunosuppressants, which often came with significant side effects and limited long-term efficacy. The paradigm shifted with the introduction of biologics like Sanofi and Regeneron's Dupixent (dupilumab), an injectable that targets specific inflammatory pathways.

More recently, a class of oral drugs known as Janus kinase (JAK) inhibitors, including AbbVie's Rinvoq (upadacitinib) and Pfizer's Cibinqo (abrocitinib), have offered patients a convenient, non-injectable alternative. These drugs work by blocking signals that drive inflammation. However, their broader mechanism has raised safety concerns, leading to regulatory warnings regarding risks of serious infections, cardiovascular events, and malignancies for the class.

It is into this complex and competitive environment that zemprocitinib aims to enter. Lynk Pharmaceuticals is positioning its drug as a 'next-generation' JAK inhibitor, engineered for high selectivity. Zemprocitinib specifically targets the JAK1 pathway, which is believed to be central to the inflammation seen in atopic dermatitis. The company suggests this precision may deliver potent efficacy while minimizing the off-target effects associated with less selective, first-generation JAK inhibitors, potentially offering a better balance of benefit and risk.

Differentiating Through Data: Efficacy and Speed

The Phase III study, led by Professor Jianzhong Zhang of Peking University People's Hospital, enrolled 356 patients who were randomized to receive one of two doses of zemprocitinib (12 mg or 24 mg) or a placebo for 16 weeks. The results were statistically unambiguous (p < 0.0001 for all key endpoints).

The study's co-primary goals were significant improvements in skin lesions, measured by the Eczema Area and Severity Index (EASI-75), and the proportion of patients achieving clear or almost clear skin (vIGA-AD 0/1). At the 16-week mark, the higher 24 mg dose of zemprocitinib resulted in 46.4% more patients achieving EASI-75 compared to placebo, while the 12 mg dose saw a 38.1% improvement. Similarly, for clear or almost clear skin, the drug outperformed placebo by 31.0% and 30.3% for the high and low doses, respectively.

A key finding that may set zemprocitinib apart is its speed of action, particularly in addressing pruritus, or severe itch—often the most burdensome symptom for patients. The trial's key secondary endpoint measured a significant reduction in worst itch, with response rates 31% higher than placebo at week 16. Notably, the company reported that statistically significant itch relief was observed as early as the first day of treatment. Improvements in skin lesions were also seen by week two, a rapid onset that could be a major draw for both patients and clinicians.

"Atopic dermatitis is a chronic, relapsing inflammatory and pruritic skin disease that imposes a substantial burden on patients' quality of life and mental health," stated Professor Jianzhong Zhang, the trial's principal investigator. "In this Phase III study, zemprocitinib demonstrated significant improvements in both skin lesion clearance and itch relief, together with a favorable overall safety profile. We look forward to the potential of zemprocitinib to provide a new oral treatment option for patients with moderate-to-severe atopic dermatitis in China."

The All-Important Safety Question

For any new JAK inhibitor, the safety profile is scrutinized as intensely as its efficacy. On this front, Lynk's announcement was reassuring. The company stated that zemprocitinib demonstrated a favorable overall safety and tolerability profile. The majority of side effects were mild to moderate, and the rates of serious adverse events or discontinuations were low and comparable to the placebo group. Crucially, no new safety signals were observed, and laboratory findings were consistent with previous studies, including a successful Phase III trial for rheumatoid arthritis. This suggests a consistent safety profile across different autoimmune conditions.

The company specifically noted no serious adverse reactions related to blood cell counts (hemoglobin, neutrophils, lymphocytes) or liver enzyme elevations—concerns that have been associated with other drugs in the class. If this clean safety profile holds up under further scrutiny and in real-world use, it could become zemprocitinib's most significant competitive advantage, offering a powerful oral therapy without the baggage of more severe safety warnings.

Lynk Pharma's Strategic Milestone

The positive data represents more than just a win for a single drug; it's a major validation of Lynk Pharmaceuticals' entire corporate strategy. The company has focused intently on developing innovative therapies for immune and inflammatory diseases, and zemprocitinib is its core asset. This success in atopic dermatitis, hot on the heels of positive Phase III results in rheumatoid arthritis, solidifies the drug's potential as a multi-indication pipeline-in-a-product.

Dr. Zhao-Kui (ZK) Wan, Founder and CEO of Lynk Pharmaceuticals, framed the achievement as a key step forward. "This achievement represents another important milestone for zemprocitinib and further reinforces its positioning as a core asset in our pipeline," he commented in the press release. "The favorable balance of efficacy and safety supports its potential differentiated profile in the competitive JAK landscape."

With a strong leadership team and now two late-stage successes for its lead candidate, the company is well-positioned to advance toward commercialization. The immediate focus will be on preparing regulatory submissions, starting with China's National Medical Products Administration (NMPA). Success there could pave the way for partnerships or independent efforts to enter lucrative Western markets, where the demand for effective and safe oral dermatological treatments remains high.

As Lynk prepares to publish the full data set and engage with regulators, the broader medical community will be watching closely. For patients struggling with the daily burden of atopic dermatitis, the prospect of a fast-acting, effective, and safe oral pill represents a significant beacon of hope on the treatment horizon.